A trial of GSK2816126 for non Hodgkin lymphoma, myeloma and other solid tumours

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

All cancer types

Status:

Closed

Phase:

Phase 1

This trial is looking at a new drug called GSK2816126 for non Hodgkin lymphoma (NHL), myeloma and other solid tumours. The trial is open to people who have a solid tumour Open a glossary item, myeloma or a type of NHL called diffuse large B cell lymphoma or follicular lymphoma that has come back after treatment.

More about this trial

Doctors can treat these cancers with

  • Chemotherapy Open a glossary item
  • Radiotherapy Open a glossary item
  • Biological therapy Open a glossary item

Unfortunately sometimes these treatments don’t work and the cancer continues to gets worse during treatment or comes back after treatment. Researchers are always looking for new treatments to help these people.

Diffuse large B cell lymphoma (DLBCL), follicular lymphoma, myeloma and other solid tumours need an enzyme Open a glossary item called EZH2 to grow. GSK2816126 is a new drug. We know from laboratory studies Open a glossary item that it can block EZH2 and so may stop these lymphomas growing. This will be the first time GSK2816126 is given to people.

There are 2 parts to this trial. In the first part the researchers want to find the highest safe dose of GSK2816126 to give. This part will be open to people with

In the 2nd part the team will use the best dose found in part 1 to treat people with DLBCL, follicular lymphoma that has transformed from low grade to high grade and myeloma.

The main aims of this trial are to

  • Find the highest safe dose of GSK2816126
  • See if it can help people with DLBCL, transformed follicular lymphoma and myeloma

Who can enter

You may be able to join part 1 of the trial if you have one of the following

And all of the following apply

  • Your lymphoma, myeloma or solid tumour  has continued to get worse during treatment or came back after treatment
  • You have satisfactory blood test results
  • You are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
  • You are willing to use reliable contraception during treatment and for 3 months afterwards
  • You are at least 18 years old

To join part 2 of the trial you must have diffuse large B cell lymphoma, myeloma or transformed follicular lymphoma with certain changes to the enzyme EZH2 (the trial team will test for this).

You cannot join this trial if any of these apply. You

  • Are currently having treatment. If you are only having steroids to control symptoms you must be stable for at least a week before taking part
  • Have prostate cancer and are on hormone therapy, apart from luteinizing hormone releasing hormone (LHRH) agonists. If you stopped your hormone therapy 4 to 6 weeks ago or are having a low dose of steroids (10mg a day) you may be able to take part
  • Have had major surgery, radiotherapy Open a glossary item or immunotherapy Open a glossary item in the past 4 weeks. If you had radiotherapy to control symptoms to a single area it must have been in the past 2 weeks. If you had a stem cell transplant using your own stem cells you can join the trial if the transplant was at least 100 days ago and you have no ongoing side effects
  • Have had chemotherapy Open a glossary item in the past 3 weeks (for continuous chemotherapy or weekly chemotherapy in the past 2 weeks)
  • Have had an experimental drug as part of another clinical trial in the past 4 weeks
  • Still have side effects from any previous treatment apart from hair loss or a drop in a type of white blood cells called lymphocytes Open a glossary item
  • Are taking certain medications (the trial team can advise you about this)
  • Are taking warfarin
  • Have certain heart problems (the trial team can advise you about this)
  • Have diabetes that isn’t controlled with medication
  • Have HIV, hepatitis B or hepatitis C
  • Have any other medical or mental health problems that the trial team thinks could affect you taking part in the trial
  • Are allergic to the drugs, or any of their ingredients, used in the trial
  • Are pregnant or breastfeeding

Trial design

This is an international phase 1 trial. Everyone will have GSK2816126.

There are 2 parts to this trial. For the 1st part the researchers need 40 people to join. For the 2nd they need 129 people.

In the 1st part, the first few patients will have a low dose of GSK2816126. If they don’t have any serious side effects, the next few patients will have a higher dose. And so on, until they find the best dose. This is called a dose escalation study.

The researchers will use the best dose of GSK2816126 they found in part 1 for part 2.

You have GSK28162126 as a drip through a central venous access device, such as a central line, portacath or PICC line. It takes 2 to 4 hours. You have it twice a week for 3 weeks and then a week of no treatment. Each 4 week period is called a cycle of treatment.
 
You can continue having GSK2816126 as long as it is helping and the side effects aren’t too bad.

The researchers will ask for a sample of your cancer that was removed when you had a biopsy Open a glossary item. If this isn’t available you must be willing to have a biopsy done before you start any treatment. The researchers will use this sample to look for the changes in the EZH2 enzyme.

The team may also ask people joining part 1 of the trial to have 2 more biopsies. They will use these samples to look for substances in the tissue (biomarkers Open a glossary item) that may tell them how well GSK2816126 is working. You don’t have to agree to have these 2 biopsies done. You can still take part in the trial.

People joining part 2, must be willing to have 2 more biopsies done. The researchers will use these to find out how GSK2816126 affects the lymphoma or myeloma.

Hospital visits

You see the doctor to have some tests before taking part in this trial. These tests include

For 24 hours after your first treatment you wear a small monitor. This will take an electrical recording of your heart beat for the 24 hours. You will stay in hospital overnight while this is been done.

During treatment you see the doctor once a week for the first 4 weeks for a physical examination and blood tests. You then see the doctor every 4 weeks for a physical examination and blood tests.

You have a heart trace on weeks 1, 2 and 3 and then every 4 weeks. You have a CT scan at week 8 and then every 12 weeks. If you have a solid tumour you have a CT scan every 8 weeks.

After treatment you see the doctor for the same tests you had at the start.

Side effects

This is the first time GSK2816126 has been tested in people so there may be side effects we don’t know about yet. The side effects may include

  • Changes to your heart beat
  • Feeling faint
  • Weakness
  • Itchiness
  • Skin rash
  • Swelling
  • Difficulty breathing
  • Skin changes, bleeding, swelling or pain at site of infusion
  • Feelings of confusion or anxiety
  • An allergic reaction causing a raised, itchy rash (hives) and swelling of the mouth or throat

A member of the trial team will talk to you about the possible side effects before you agree to take part in the trial.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor P Johnson

Supported by

Experimental Cancer Medicine Centre (ECMC)
GlaxoSmithKline (GSK)

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

12807

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Cara took part in a clinical trial

A picture of Cara

"I am glad that taking part in a trial might help others on their own cancer journey.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think